Erudio Healtherudio.com
Drug
Elotuzumab trials: what clinicians said in public
HCP commentary reports on 3 clinical trials studying elotuzumab: CEVOLUTION, GMMG-HD6 and MonumenTAL-6. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 9 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| MonumenTAL-6 NCT06208150 · Janssen Research & Development, LLC | relapsed or refractory multiple myeloma | Phase 3 | 537 | 41 | Deep | Nov 16, 2026 | Preview |
| GMMG-HD6 NCT02495922 · University of Heidelberg Medical Center | newly diagnosed multiple myeloma | Phase 3 | 185 | 20 | Standard | Nov 15, 2026 | Preview |
| CEVOLUTION NCT07555938 · Hoffmann-La Roche | previously treated multiple myeloma | Phase 3 | 8 | 1 | Focused | Nov 9, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| KarMMa-3 NCT03651128 · Celgene DeepView → | triple-class-exposed relapsed and refractory multiple myeloma | Phase 3 | Deep | View | |||
| CERVINO NCT06158841 · AbbVie DeepView → | relapsed or refractory multiple myeloma | Phase 3 | Deep | View | |||
| S1211 NCT01668719 · SWOG Cancer Research Network DeepView → | newly diagnosed high-risk multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| ELOQUENT-2 NCT01239797 · Bristol-Myers Squibb StandardView → | relapsed or refractory multiple myeloma | Phase 3 | Standard | View | |||
| LINKER-MM3 NCT05730036 · Regeneron Pharmaceuticals StandardView → | relapsed/refractory multiple myeloma | Phase 3 | Standard | View | |||
| CC-92480-MM-002 NCT03989414 · Celgene FocusedView → | relapsed, refractory or newly diagnosed multiple myeloma | Phase 1/Phase 2 | Focused | View | |||
| MagnetisMM-32 NCT06152575 · Pfizer FocusedView → | relapsed/refractory multiple myeloma with prior anti-CD38 therapy | Phase 3 | Focused | View | |||
| DSMM XVII NCT03948035 · Wuerzburg University Hospital FocusedView → | Not given | Phase 3 | Focused | View | |||
| NCT05028348 NCT05028348 · European Myeloma Network B.V. FocusedView → | Not given | Phase 3 | Focused | View | |||